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Abstract 
Chronic wounds fail to proceed through an orderly and timely self-healing process, resulting 
in cutaneous damage with full thickness in depth and leading to a major healthcare and 
economic burden worldwide. In the UK alone, 200,000 patients suffer from a chronic wound, 
whilst the global advanced wound care market is expected to reach nearly $11 million in 2022. 
Despite extensive research efforts so far, clinically-approved chronic wound therapies are still 
time-consuming, economically unaffordable and present restricted customisation. In this 
chapter, the role of collagen in the extracellular matrix of biological tissues and wound healing 
will be discussed, together with its use as building block for the manufacture of advanced 
wound dressings. Commercially-available collagen dressings and respective clinical 
performance will be presented, followed by an overview on the latest research advances in 
the context of multifunctional collagen systems for advanced wound care. 
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13.1 Introduction 
Chronic wounds, also referred to as hard-to-heal ulcers, fail to proceed through an orderly 
and timely self-healing process, resulting in cutaneous damage with full thickness in depth. 
Chronic wounds typically take longer than 3 months to heal, and can originate from prolonged 
application of pressure to the skin (pressure ulcers), diabetes-related reduced nerve function 
and poor blood circulation (diabetic ulcers), improper functioning of venous valves (venous 
ulcers), and arterial narrowing at the lower extremities (arterial insufficiency ulcers). Clinical 
complications arising from this pathology include infection, gangrene, haemorrhage and lower-
extremity amputations, potentially resulting in permanent disabilities and pain for patients.  
Chronic wounds are a major healthcare and economic burden worldwide. In the UK alone, 
200,000 patients suffer from a chronic wound, whilst more than 6 million people are affected 
in the United States of America [1,2]. Due to the increasing rates of diabetes and obesity as 
well as an ageing population, it is estimated that 1-2% of the general population will develop 
a chronic wound, and up to 25% of the patients with diabetes will be affected by an ulcer in 
their lifetime [3]. Consequently, the global advanced wound care market, including advanced 
wound dressings, negative pressure wound therapy (NPWT), wound care biologics and other 
products, is expected to reach nearly $11 million in 2022, growing at a CAGR of 5% from 2016 
to 2022 [4]. Due to their easy applicability and availability as well as clinical competence, 
advanced wound dressings accounted for the largest market share of the advanced wound 
care technology market in 2015. There is therefore growing attention towards the design of 
advanced dressing devices that can accelerate healing in chronic wounds by recapitulating 
aspects of the wound healing microenvironment, and that can be customised according to 
stratified wound populations, to improve patients’ quality of life, to reduce healthcare costs and 
to create patient-friendly solutions. 
 
13.1.1 Clinical need of advanced wound dressings  
Wound healing is a dynamic process, which proceeds via overlapping phases of 
inflammation, epidermal restoration, wound contraction and remodelling (Figure 13.1). This 
process relies on the dynamic interaction of cells, soluble factors and the extracellular matrix 
(ECM), so that inflammation can rapidly be resolved to allow for the ingrowth of fibroblasts and 
keratinocytes [5]. Activation of platelets and secretion of inflammatory cytokines, migration of 
macrophages, fibroblasts and keratinocytes as well as expression of matrix 
metalloproteinases (MMPs) and growth factors are key to promote wound contraction and 
closure, ultimately leading to mature ECM and the formation of functional neo-tissue.  
 
Figure 13.1. Typical healing and impaired healing phases in normal and hard-to-heal wounds, 
respectively.   
 
Especially the release of MMPs in a balanced and coordinated fashion is crucial to enable 
phagocytosis, angiogenesis, cell migration during epidermal restoration, and tissue 
remodelling. Such cascade of timely events is impaired in chronic wounds and results in a 
persistent inflammation state, which is associated with upregulated MMPs and reactive 
oxidative species (ROS), impaired growth factor expression, and increased risks of bacterial 
contamination [6]. MMP activity has been reported to be up to 30-fold higher in chronic 
compared to acute wound fluids, suggesting that new extracellular matrix (ECM) is 
continuously broken down due to the imbalanced ratio between MMPs and tissue inhibitors of 
MMPs (TIMPs). In light of the orchestrated nature of the wound microenvironment, observed 
MMP upregulation negatively affects fibroblast response and differentiation and cause growth 
factor denaturation at the wound site, so that the subsequent healing steps are halted.  
The use of topical wound dressings is a recognised way to wound healing (Figure 13.2). 
Initially intended to keep the wound dry to minimise wound infection, conventional dressings 
were subsequently designed to absorb and retain wound exudate in order to enhance healing 
rates. Highly-hydrated fibrous assemblies have therefore been realised [7], yet a narrow trade-
off between dressing exudate absorbency and hydrated mechanical properties is commonly 
observed in situ. Consequently, self-adhesive oxygen-permeable film dressings have been 
developed to allow for moisture evaporation from intact periwound skin.  
 Figure 13.2. Design concept of an advanced wound dressing regulating wound exudate levels at the 
macroscopic scale, as well as pH and overexpressed MMPs and ROS at the biochemical level.   
 
Ultimately, with the advances in biomaterials science, textile manufacture and skin biology, a 
technology design shift has been pursued from dressings intended as purely skin-protecting 
bandages to advanced wound dressings, aiming to regulate wound microenvironment with 
regards to e.g. pH, proteolytic activity and ROS concentrations. An array of approaches of 
varying efficacy has therefore been pursued, including MMP-cleavable sacrificial substrates 
[8], metal-chelating chemistries [9], cell [10] and soluble factor [11] delivery strategies, 
keratinocytes migration-inducing peptides [12], bio-responsive systems [13] and growth factor-
delivering vehicles [14]. Despite extensive research efforts so far, clinically-approved 
therapies for chronic wound management are still time-consuming, economically unaffordable 
and present restricted customisation.  
In this chapter, the role of collagen in the ECM of biological tissues and wound healing will 
be discussed, together with its use as building block for the manufacture of advanced wound 
dressings. Commercially-available collagen dressings and respective clinical performance will 
be presented, followed by an overview on the latest research advances in the context of 
multifunctional collagen systems for advanced wound care. 
 
 
13.2 Collagen as building block of advanced wound dressings 
Collagen is the most abundant protein in the human body. As a structural protein produced 
by fibroblasts, it plays a major role in all phases of the wound healing cascade, stimulating 
cellular activity and contributing to new tissue development [15]. The presence of collagen in 
wound dressings is therefore highly advantageous to promote healing in hard-to-heal wounds, 
by encouraging the migration of macrophages and fibroblasts to the wound site, leading to the 
deposition of new collagen matrix. Other than its chemotactic effect on wound specific cells, 
collagen is also highly hydrophilic, so that respective collagen dressings promote the uptake 
of growth factors- and MMP-rich wound exudate [16]. Collagen-driven uptake of wound 
exudate is key not only to keep the wound hydrated, but also aiming to bind and protect wound 
exudate-carried growth factors, as well as to inactivate upregulated, tissue detrimental chronic 
wound MMPs, so that neo-tissue is not constantly enzymatically degraded. With the increased 
elucidation on the role that biochemical factors play in chronic wounds and in light of recent 
advances in biomaterials science, a great deal of attention has therefore been devoted to the 
development of advanced collagen-based dressing formulations aiming (i) to provide 
dressings with superior enzymatic stability at the macroscopic level, (ii) to regulate the chronic 
wound microenvironment at the biochemical level, and (iii) to successfully enable their 
customisation to fulfil the requirements of a wide range of chronic wound populations. 
 
13.2.1 Protein composition and organisation in vivo 
Collagen accounts for about one-third of the proteins in humans and two-thirds of the skin 
dry weights. As the most abundant protein in mammals, collagen has provided mankind with 
widespread applicability. In vivo, it plays a dominant role in maintaining the biological and 
structural stability of various tissues and organs. Ex vivo, collagen has been widely employed 
in the development of leathers and glues, food, cosmetic and pharmaceutical formulations, as 
well as in medical devices [17]. So far, 28 genetically-distinct types of collagen have been 
identified, with all of them displaying a triple helical structure at the molecular level (Figure 
13.3).  
 
Figure 13.3. Stabilised collagen fibril assemblies present in skin’s ECM.  
 
Of these, type I (found in skin, tendon, and bone), II (found in cartilage), and III (found in skin 
and vasculature) are mostly employed for biomedical applications, and are characterised by 
collagen triple helices assembled into fibrils at the nanoscale, which are responsible for tissue 
architecture and integrity. The remarkable industrial versatility of collagen can therefore be 
largely attributed to its hierarchical organisation.   
The collagen molecule is based on three left-handed polyproline II-type (PPII) helices, 
which are staggered from one another by one amino acid residue and are twisted together to 
form a right-handed triple helix (300 nm in length, 1.5 nm in diameter). Triple helices (THs) 
can be either homo- or heterotrimers, depending on the tissue and collagen type. With regards 
to collagen type I, which is widely used in wound care and regenerative medicine, the triple 
helix consists of a heterotrimer of two α1(I) chains and one α2(I) chain [18]. At the molecular 
level, each TH-forming PPII helix contains ca. 1000 amino acid residues, and is characterised 
by the repeating unit Glycine-X-Y, whereby X and Y are predominantly proline and 
hydroxyproline, respectively. The high content of both stiff (hydroxyl-)proline and small glycine 
residues explains the folding of each polypeptide into a PPII helix and the consequent 
arrangement of three PPII helices in the right-handed triple helix. Depending on the location 
in the human body and the specific biological tissue, THs can assemble into fibrils, fibres and 
fascicles. Besides secondary interactions, collagen assemblies, i.e. THs, fibrils, fibres and 
fascicles, are stabilised via covalent crosslinks, which are formed between (hydroxy-)lysine 
residues under the influence of lysyl oxidase via either aldol condensation or Shiff base-
mediated mechanism [19]. These naturally-occurring intra- and intermolecular crosslinks are 
formed in the non-helical, telopeptide regions of the collagen molecule; they are responsible 
for the proteolytic resistance of collagen in vivo and contribute to the mechanical properties 
and biological function of tissues.  
Above-mentioned chemical composition and structural organisation explains the 
importance of collagen in wound healing and its widespread use for the manufacture of 
advanced wound dressings. The presence of the integrin recognition amino acidic sequences 
RGD and GFOGER along PPII helices enables collagen to control many cellular functions of 
fibroblasts and keratinocytes, including cell shape, differentiation and migration. Type I 
collagen has been reported to stimulate angiogenesis in vitro and in vivo via binding of 
endothelial cell (EC) surface α1β1 and α2β1 integrin receptors by the GFPGER502-507 
sequence of the collagen triple helix [20]. The amino acidic sequences of collagen also serve 
as binding sites for a number of chronic wound-upregulated inflammatory cytokines and 
MMPs, making collagen biodegradable. Besides promoting the migration of skin cells towards 
the wound, the application of collagen dressings can also divert tissue detrimental action of 
aforementioned enzymes and soluble factors from the chronic wound to the dressing, offering 
an inherent mechanism of wound microenvironment regulation towards healing. 
 
13.2.2 Extraction of collagen ex vivo  
Aiming to use collagen as the building block of advanced wound dressings, collagen is 
extracted from biological tissues, e.g. tendons, in acidic environments or via 
enzyme-catalysed extraction. Collagen fibers in vivo are stable enough to withstand the 
disruptive influence of thermal agitation but capable of the assembly and disassembly of the 
component molecules. However, irreversible disassembly of collagen can be induced ex vivo 
by several agents, such as heat, pH, and enzymatic action. In these situations, the weak bonds 
(hydrogen bonds, dipole-dipole bonds, ionic bonds, and van der Waals interactions) are 
initially broken, followed by the chemical cleavage of covalent crosslinks. Collagen molecules 
in the form of triple helices become therefore soluble and diffuse away from the tissue to the 
extracting medium. Consequently, the unique hierarchical organisation of collagen found 
vivo is lost ex vivo, resulting in a water-soluble product with limited solubility in organic 
solvents. Extracted collagen triple helices can be reconstituted in vitro (pH 7.4, 37 ºC) into in 
vivo-like fibrillary structures, resulting in viscoelastic gels at the macroscopic level; yet poor 
mechanical stability and uncontrollable volumetric swelling are usually observed in aqueous 
environment.  
Whilst the extraction of collagen is typically carried out in mild conditions, so that collagen 
triple helices can be preserved and collected, excessive heating and extremely acidic solution 
pH can lead to denatured collagen, whereby triple helices unwind into single random coils, 
and cleavage of pristine collagen polypeptides into smaller chains occurs. Such denatured 
form of collagen is called gelatin, which is a heterogeneous mixture of water-soluble 
polypeptide chains of varied molecular weights. Gelatin usually binds more water than 
collagen in light of its randomly-coiled conformation, whereby an increase number of functional 
groups are exposed to water, leading to new hydrogen bonds. Based on their chemical 
similarities and compatibility within the body, collagen and gelatin are both widely used as 
building blocks for the design of multifunctional biomaterials and the manufacture of advanced 
wound dressings. Gelatin is a much cheaper raw material than collagen, and that is why it is 
often employed in place of collagen. Due to the presence of triple helices and higher molecular 
weight of PPII helices, collagen shows restricted solubility compared to gelatin, although 
collagen-based materials typically exhibit increased mechanical competence in hydrated 
conditions. Consequently, flexible chemical and manufacturing processes should be 
developed to enable collagen applicability in clinical settings towards the development of in 
vivo-like covalently-crosslinked collagen networks, which are water-insoluble, elastic and that 
can be configured in bespoke macroscopic formats, such as nonwoven fabrics, coatings as 
well as pads. 
 
13.2.3 Collagen sources and antigenicity  
Type I collagen has been successfully extracted from either bovine, equine, or porcine 
tissues and employed in commercial advanced wound dressings, e.g. Promogran®, Biopad® 
and Biostep®. However, the use of animal-derived collagen is associated with religious 
constraints, potential allergies and concerns of transmissible diseases, especially bovine 
spongiform encephalopathy (‘‘mad cow disease’’). Synthetic research approaches leading to 
either collagen-like macromolecules or collagen triple helix-mimicking peptides have been 
proposed as chemically viable ‘artificial’ collagen [21, 22]. Likewise, genetic engineering 
strategies have been successfully pursued to achieve type I recombinant human collagen as 
pathogen-free, economically affordable and quality-controlled raw material [23]. On the other 
hand, alternative collagen sources, such as fish [24,25] and chicken [26] skin, have been 
explored to address above-mentioned issues in translation and commercialisation settings, 
and to comply with current regulatory framework. Tissue source is known to affect the 
extraction yield and the chemical composition and clinical performance of resulting collagen 
[27], whereby differences in amino acid composition (e.g. lower imino acid and lysine content 
in fish compared to bovine collagen) have been found to impact on thermal, structural and 
mechanical properties, covalent crosslinking, and, above all, antigenicity [28]. With regards to 
the latter point, the use of a human collagen would minimise the probability of interspecies 
variability and immune rejection, whilst the concept of material purity should also be carefully 
considered. Therefore, reliable extraction and manufacturing processes should be developed, 
to minimise the contamination of collagen products with unwanted residues related to non-
collagenous proteins, cells, crosslinking compounds, or microbial components, i.e. endotoxins 
[29]. 
The selection of collagen sources with minimal antigenicity is prerequisite to enable clinical 
use of collagen dressings in humans and to minimise the potential to evoke immune and 
adverse reactions. Macromolecular features present in the collagen backbone not common to 
the host species are more likely to interact with antibodies and to encourage an immune 
response than shared features, thereby acting as antigenic determinants. Interspecies amino 
acidic variation is therefore inherently linked to the issue of collagen antigenicity. Hence, the 
immunological closeness to humans supports the widespread use of bovine collagen for the 
development of commercial wound dressings with minimal antigenicity. Antigenic 
determinants of collagen can be found in the (triple) helical regions, with variations in the 
amino acid sequences not exceeding more than a few percent between mammalian species 
[30]. A far greater degree of variability is found in the non-helical terminal regions of collagen, 
i.e. telopeptides, with up to half of the amino acid residues in these regions exhibiting 
interspecies variation. Telopeptide-free collagen, also called atelocollagen, can be obtained 
via pepsin-induced extraction [31], whose yield is reported to be higher compared to acidic 
extraction [32]. The introduction of pepsin in the extraction medium allows for the selective 
cleavage of peptide bonds located in the terminal non-helical regions, potentially reducing 
collagen antigenicity. The telopeptide ends of the collagen molecule are dissected, whilst the 
triple helices remain preserved. The removal of telopeptides may on the other hand result in 
the inability of reconstituted product to display characteristic collagen fibril patterns, due to the 
role amino and carboxyl telopeptides play in crosslinking and fibril formation [28,30]. 
 
13.3 Commercial collagen dressings 
Collagen has been widely investigated as building block of commercial advanced wound 
dressings, whereby varied protein and chemical configurations have been proposed to 
achieve superior wound healing dressing function. The application of hydrophilic dressings 
with appropriate exudate management capability is a recognised route to chronic wound 
healing [33]. Transparent collagen dressings have been developed in the form of membranes, 
pads and gels, allowing for wound monitoring and uptake of growth factor-rich wound exudate, 
whilst providing a barrier to exogenous bacteria. With the increasing understanding of the 
chronic wound microenvironment, multiphase formulations have also been pursued aiming to 
integrate collagen-based dressing devices with multiple functions, such as antibacterial 
activity, drug release as well as wound cleansing and MMP management capabilities (Table 
13.1).  
 
Table 13.1. Examples of patented, commercially-available collagen-based advanced wound dressings. 
Product 
ID Composition 
Collagen 
conformation 
Collagen 
content [wt.%] Format Ref. 
Biopad 100% type I native equine collagen Triple helix 100 Pad [34] 
Puracol 100% bovine collagen, Manuka honey Triple helix 88 Pad [38] 
Stimulen Bovine collagen, glycerin Hydrolysed 52 Gel [48] 
Promogran Bovine collagen, oxidized regenerated cellulose Hydrolysed 55 Pad [51] 
ColActive 
Gelatin, sodium alginate, 
carboxymethylcellulose, EDTA, 
plasticisers 
Denatured 50-90 Mesh [53] 
 
 
13.3.1 Non-hydrolysed collagen formulations 
Nonporous dressing pads made of 100% type I equine non-hydrolysed collagen have been 
developed and commercialised (Biopad®) for the therapeutic treatment of burns and wounds 
[34]. Here, the hydrophilic behaviour of collagen was exploited to promote absorption (up to 
15 times of the material dry weight) of wound exudate and aqueous biological media in the 
dressing. The dressing product consists of a non-fibrous pad of chemically unmodified 
collagen, which is prepared by sequential collagen acidic solubilisation, filtering and drying. 
The fact that the material is nonporous and chemically-unmodified may be beneficial (i) to 
control and slow down the rapid dressing-induced exudate uptake (due to the presence of a 
compact, pore-free structure), which may otherwise lead to detrimental and excessive wound 
evaporation; (ii) and to preserve the native collagen biological function and triple helix structure 
in resulting product. Especially the retention of triple helices is key to allow for collagen binding 
with wound exudate growth factors and cytokines and to ensure mechanical competence in 
the hydrated state [35]. The resulting collagen dressing pad is amenable to surgical cutting to 
fit the size of the wound. Prior to application in situ, the dressing should be partially hydrated 
to gain elasticity and to conform to the wound, likely due to the glassy-like behaviour of 
collagen in the dry state and the absence of any plasticising phase in the dressing [36]. 
Following hydration with wound exudate in situ, the collagen dressing is claimed to be 
transparent, allowing for continuous wound monitoring, so that frequent dressing removal and 
replacement can in principle be avoided (although a secondary dressing is normally applied 
to maintain the dressing pad at the wound site). Besides the inherent advantages associated 
with its 100% non-hydrolysed triple helix-preserved collagen composition, this dressing was 
also reported to exhibit optimal structural compromise with regards to the extension of the 
collagen areas and the thickness of the collagen strands. Although no information on the MMP 
regulation capability was disclosed, these dressings proved to retain the same overall 
structure during exposure to collagenase [37]. Aiming at a dressing device with additional 
biochemical and wound cleansing capabilities, a non-hydrolysed collagen-based formulation 
(Puracol®) was proposed containing Manuka honey (MH) [38]. The use of MH in the dressing 
is rationalised by the fact that wound cleansing of necrotic tissue is typically required prior to 
wound dressing treatment; this is usually carried out via surgery or sharp debridement, which 
may cause patient pain and require additional nursing time. Here, bovine collagen was 
employed to induce MMP regulation via collagen binding and cleavage with MMPs, and was 
still applied in its non-hydrolysed, triple helix, and non-crossinked state. Other than controlling 
MMP overexpression in chronic wounds, the use of collagen was also expected to increase 
the viscosity of MH aiming to achieve localised delivery to the wound site, minimising MH 
spillage out of it. The use of MH was first intended to promote debridement of necrotic tissue 
following dressing application in situ, although MH activity is expected to positively impact on 
wound healing over different levels: (i) its acidity induces temporal denaturation of MMPs, 
which are responsible for wound chronicity; (ii) MH osmolarity draws wound exudate out of 
the wound bed, resulting in an outflow of fluid, which helps dissolving necrotic tissue and 
cleansing the wound [39]; (iii) MH has broad-spectrum antibacterial activity even when in 
contact with high amounts of wound exudate, largely attributed to the presence of 
methylglyoxal [40,41].The proposed formulation combining the advantages associated with 
collagen and MH can be employed as wound contacting layer within a multilayer dressing 
comprising a (non)woven fabric, an absorbent layer made of e.g. polyurethane foam or 
cellulose fibres, and a fluid impervious, adhesive cover layer designed to contain the wound 
exudate absorbed by the dressing. The wound cleansing and healing performance of the 
collagen layer was successfully investigated in patients with hard-to-heal wounds. Here, 
decrease in depth, increase in granulation tissue and decrease in the overall wound size 
provided evidence of the wound conversion from a chronic to a proliferative state within a 3-
week time window [42], These findings demonstrated the beneficial function of the native 
collagen dressing towards the preparation of an optimal wound bed, ultimately leading to 
accelerated wound re-epithelialisation. On the other hand, the dressing potential to manage 
MMP upregulation in situ was not specifically addressed. 
Non-hydrolysed type I equine collagen has also been recently combined with hyaluronic 
acid (HA) [43] aiming to realise a dressing pad capable to promote cell proliferation, migration, 
differentiation, and angiogenesis, whilst also inducing hydration of the wound [44]. The use of 
HA is rationalised since HA is a glycosaminoglycan found in the ECM that plays a central role 
in controlling water content and mechanical function of connective tissues, whilst also 
regulating several processes related to cell physiology and biology via interaction with specific 
cell receptors [45].  
Aiming to preserve both collagen proteolytic activity and HA biofunctionality and keep the 
dressing pad manufacture simple, the formulation is prepared with no covalent crosslinks or 
chemical functionalisation at the molecular level. Solutions containing specific ratios of HA and 
collagen are freeze-dried so that the final dressing pad is achieved ready for sterilisation. The 
application of freeze-drying to the polymer solution enables the formation of pores in resulting 
dressing internal architecture [46], thereby enhancing the exudate absorption capacity of the 
dressing (Figure 13.4). Despite the absence of any covalent crosslink between the two 
phases, carboxylic acid groups of HA are expected to electrostatically interact with the amino 
groups of collagen, resulting in the formation of a physical network at the molecular scale. In 
light of the addition of HA, resulting dressing is mechanically strong yet flexible, in contrast to 
the case of collagen only pad [34], and can promptly conform to topical wounds.  
 
Figure 13.4. Manufacture and scanning electron microscopy (SEM) of a dressing pad obtained via 
freeze-drying of a gelatin aqueous solution.  
 
Other than wound dressing pads, the HA-collagen formulation can also be delivered in the 
hydrogel state for the treatment of cavity wounds. Culture of 3T3 fibroblasts with both collagen-
HA and collagen control formulations confirmed that the use of HA promoted increased 
adherence of seeded cells to the material with respect to the collagen control, within a 5-day 
time window. Also in this case, the performance of the HA-collagen dressing prototype in 
contact with MMPs was not addressed. 
 
13.3.2 Hydrolysed collagen-based formulations 
Extraction of collagen with preserved triple helices requires defined and controlled 
experimental conditions. Once extracted ex vivo, collagen in its triple helix state is known to 
present limited solubility and time-consuming solubilisation in aqueous conditions, which limit 
the creation of scalable customised material format. To overcome above-mentioned 
constraints and identify cost-effective biochemically-comparable alternatives, extensive 
research and development has been carried out with derived, either hydrolysed or denatured, 
forms of collagen, which have been successfully integrated in several commercially-available 
advanced wound dressings. In contrast to native collagen, hydrolysed or denatured (i.e. 
gelatin) derivatives consist of a wide mixture of predominantly linear polypeptides. These 
random coils can however refold into collagen-like triple helices, depending on the 
environmental conditions and polypeptide molecular weight, so that uncontrollable structure-
property relationships may be observed [47]. A modified collagen gel (MCG) formulation 
(StimulenTM) comprising non-crosslinked, hydrolysed bovine collagen mixture of long and 
short polypeptides dispersed in a matrix of water and glycerine has been disclosed for the 
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treatment of ischemic wounds [48]. Preclinical investigations in an excisional wound swine 
model showed that MCG-treated wounds displayed longer rete ridge structures compared with 
untreated wounds, suggesting improved biomechanical properties of the healing wound 
tissue. The hydrolysed collagen formulation also proved to improve recruitment of neutrophils 
and release of inflammation-related cytokines into the wound site [49]. Despite lacking its 
native triple helix structure, the application of hydrolysed collagen in situ was still effective in 
promoting an initial boost in macrophage concentration and inflammatory response, followed 
by rapid return of macrophage count to control values and inflammatory resolution, so that 
healing could take place [50]. Consequent to these results, hydrolysed collagen was blended 
with oxidised regenerated cellulose (ORC) to create a dressing pad (Promogran®) combining 
superior water absorption properties of cellulose with wound-regulating biochemical 
functionalities of collagen [51]. The dressing preparation involved the solubilisation of bovine 
hydrolysed collagen (BHC) and ORC in an aqueous solution, followed by one-pot freeze-
drying and dehydrothermal crosslinking process. The final material therefore consists of a 
mechanically strong pad, which can be surgically cut to fit the wound size, yet displaying 
restricted elasticity, likely consequent to the presence of covalently-crosslinked, low molecular 
weight collagen polypeptides. In contrast to previously-discussed products, results on the 
BHC/ORC dressing performance in diabetic foot ulcers wound fluid confirmed the material 
ability to successfully bind and rapidly inactivate chronic wound proteases [52], although no 
information on the potential dressing mass loss consequent to proteolytic cleavage was 
provided. Overall, these results underline that the BHC/ORC formulation could remove excess 
proteases from the wound bed, so that the enzyme-induced tissue degradation could be 
reduced and tissue synthesis promoted. Despite hydrolysed rather than triple helix preserved 
collagen was employed in this dressing, these results demonstrate that the collagen 
polypeptide can still act as a competitive enzymatic substrate with respect to the neo-tissue. 
Other than the collagen-based mechanism, the addition of ORC in the dressing was 
demonstrated to provide an additional means for MMP regulation via electrostatic 
complexation of ORC negatively charged functional groups with positively charged metal ions 
found in physiological conditions and essential for MMP activity. Hydrolysed collagen was also 
demonstrated to bind with and protect platelet-derived growth factor (PDGF) from proteolytic 
degradation, suggesting the potential applicability of the BHC/ORC dressing as controlled 
delivery system. Moreover, the dressing was also demonstrated to serve as free radical 
scavenger, which is key to control the excessive upregulation of reactive oxygen species 
responsible for the prolonged inflammatory state in chronic wounds. The multiple biochemical 
functions exhibited by the BHC/ORC dressing proved key to induce significantly increased 
wound closure in diabetic mice in contrast to dressing-free control wounds [8]. These results 
were found in agreement with histological analysis of wound tissue 14 days post-wounding, 
whereby enhanced formation and maturation of granulation tissue was observed in 
BHC/ORC-treated wounds. Other than hydrolysed collagen, porcine gelatin has been 
employed for the manufacture of flexible mesh dressings, together with a biocompatible 
plasticiser, such as polyethylene glycol (PEG), carboxymethylcellulose (CMC), sodium 
alginate and ethylenediaminetetraacetic acid (EDTA) [53]. During manufacture, the dressing-
forming aqueous mixture is poured on to a fibrous substrate of e.g. cellulose prior to freeze-
drying. The use of the plasticiser in the dressing formulation provides the dressing with 
enhanced elasticity in the dry state, in contrast to previously mentioned collagen-based 
dressing pad products, whilst CMC and sodium alginate are employed as hydrophilic 
component to enhance the absorption capacity of the material in situ. Despite gelatin is 
crosslinked by carbodiimide-induced intramolecular crosslinking, a 20 wt.% mass loss was 
recorded following 24-hour incubation with collagenase. To further control collagenase 
activity, EDTA is introduced in the dressing as soluble metal chelator, aiming to induce 
complexation with the active zinc site of upregulated MMPs, thereby providing an additional 
mechanism for MMP inactivation. Although the extent of degradation was reduced in the 
presence of alginate, the structure was observed to collapse following 5-hour exposure to 
collagenase at body temperature [37], whilst a water uptake of up to 34-time the initial dressing 
dry weight was observed following 24-hour incubation (0.01 M PBS, pH 7.4, 37 ºC). The 
presence of plasticisers effectively enhanced the elasticity of the material following 1-hour 
soaking in PBS (0.01 M, pH 7.4), resulting in a measured elongation at break of more than 
190%. Ultimately, resulting dressing mesh could be loaded with Sirolimus as exemplary anti-
inflammatory drug for the controlled delivery to the surface of tissues, whereby less than 2% 
drug was released after 3 days in vitro (0.01 M PBS, pH 7.4, 37 ºC). 
 
13.4 Design of multifunctional collagen systems with customised formats 
Despite wound management collagen solutions have been commercialised to respond to 
the pressing needs of an increasing diabetic population, limitations in biochemical 
functionalities, manufacturing processes and customisation of dressing properties, functions 
and format prevent us from developing cost-effective technologies personalised for a wide 
range of chronic wounds. To address this challenge, widespread research has been pursued 
to design multifunctional systems with bespoke architecture and integrated bioactive 
formulations, aiming to correct chronic wound biochemical imbalances and achieve dressing-
induced orchestration of the wound healing microenvironment. Research strategies to realise 
this have focused on three main streams: (i) cell-based therapies, whereby cells are 
encapsulated in the dressing material to promote tissue repair [54,55]; (ii) drug-loaded 
systems enabling controlled and staggered release of soluble factors to prevent wound 
infection and accelerate healing [56,57]; (iii) cell- and soluble factor-free dressing devices 
whereby the healing functionality is inherently accomplished by dressing physical properties 
and chemical configurations at the molecular scale [58,59]. The design of inherently 
multifunctional wound dressings may be preferable to achieve constant clinical performance 
in vivo, irrespective of temporal factors ruling e.g. the release of active compounds or 
metabolic activity of encapsulated cells, whilst also minimising regulatory framework 
constraints and time required for regulatory approval and translation to market.  
 
 
 
13.4.1 Synthesis of network architectures to achieve dressing multifunctionality 
Despite collagen is an ideal biomaterial for wound dressing application, the inherent 
MMP-induced degradation in vivo of collagen-based dressings raises concerns in terms of 
dressing form-stability, non-controllable swellability, and poor hydrated mechanical properties. 
Incorporation of soluble MMP-chelating agents, i.e. EDTA, has been exploited for the 
development of commercial advanced wound care products. Yet, loading of the dressing with 
soluble factors may involve additional considerations with regards to controlled release 
kinetics, sustained MMP modulation and medicinal product-related translation pathway. Either 
glutaraldehyde [60,61], genipin [62], carbodiimide chemistry [63], or physical factors [64,65] 
have been employed to stabilize collagen in biological environments, although issues remain 
with regards to material cytotoxicity and restricted control of crosslinking reaction and material 
properties. To overcome these limitations, a great deal of attention has been given towards 
the development of flexible crosslinking strategies of collagen. By introducing crosslinks 
between collagen molecules, water-insoluble networks are accomplished that swell in contact 
with wound exudate, so that defined moist environment is established in situ, whilst enhanced 
dressing biodegradability and hydrated mechanical properties can be expected. Most 
importantly, additional biofunctionalities can be introduced in resulting materials depending on 
the characteristics of the crosslinking segment. 
Type I bovine collagen has been crosslinked with tannic acid in an effort to introduce the 
antimicrobial and anti-inflammatory activities of tannic acid within a covalent collagen matrix 
[66]. Tannic acid (TA) is a plant polyphenol consisting of a glucose moiety core with hydroxyl 
groups being esterified with five digallic acids. Resulting materials proved to display about 10 
wt.% mass loss following 42-hour incubation in a collagenase-containing medium, in contrast 
to more than 60 wt.% mass loss observed in tannic acid-free collagen controls in the same 
conditions. Following application to full-thickness wounds in rats, TA-crosslinked samples 
proved to support enhanced wound closure and nearly-complete re-epithelialisation following 
12-day treatment, in comparison with the collagen control, whilst no commercial benchmark 
was employed in the study. Results obtained in vitro and in vivo therefore support the 
hypothesis that TA carboxylic and hydroxyl groups within the collagen matrix can mediate the 
formation of non-covalent net-points with the functional groups of the collagen molecules, 
explaining the decreased degradation yield. Digallic acid units are also known to act as metal 
ion chelators; they can therefore bind with and inhibit collagenases [67], contributing to the 
accelerated healing observed in wounds treated with TA-based collagen formulations. 
Building on the knowledge developed with this system, Francesko et al. analysed the 
enzymatic modulation activity of plant polyphenol-loaded type I bovine collagen-based 
co-networks prepared via carbodiimide-catalysed crosslinking reaction with either hyaluronic 
acid or chitosan [68]. Hydrogels displayed an averaged swelling ratio of 1500-2500 wt.% and 
an averaged Young’s modulus of 60-160 kPa, depending on the specific formulation. Here, 
the addition of hyaluronic acid proved to significantly impact on the water uptake capability of 
resulting samples, in agreement with the well-known swellability of hyaluronic acid in vivo. 
Despite that, increased material stability was observed in enzymatic media, whereby collagen 
degradation was measured in the range of 10-30 wt.% following 1-day incubation with 
collagenases. The release profile of loaded polyphenols was not addressed, yet no toxic 
response and spread-like cell morphology was observed following 3-day culture with L929 
fibroblasts. Following similar line of thinking, either Macrotyloma uniflorum or Triticum 
aestivum were loaded as anti-inflammatory and antibacterial plant extract onto fish 
collagen-fibrin composites [69] and goat tendon collagen aerogels [70], respectively. 
Collagen-based composites displayed more than 40 wt.% mass loss following 24-hour 
incubation in enzymatic media, partially explained by the absence of any covalent crosslinks; 
yet, they induced accelerated healing of full thickness wounds in albino Wistar rats via 
suppression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthases (iNOS) and MMP-
9 expressions [71]. On the other hand, triticum aestivum was shown to promote chemical 
crosslinking of collagen lysines [70], so that triticum aestivum-loaded collagen aerogels 
displayed proangiogenic effect resulting in complete wound closure in female wistar rats 
following 18 days post-wounding. Besides the biochemical modulation of the wound 
microenvironment, sponges of denatured collagen and hyaluronic acid were realised and 
loaded with epidermal growth factor (EGF), aiming to stimulate cell proliferation for the 
treatments of burns [72]. The absence of covalent crosslinks between the two biopolymers 
was likely responsible for the quick dissolution of the sponge within 7-day incubation, although 
the consequent quick EGF release proved beneficial in promoting angiogenesis and 
re-epithelialisation in a dermal burn model in rats [73] as well as in a full-thickness dorsal skin 
defect in diabetic mice [74]. Other than loading with soluble bioactives to achieve specific 
modulation of the wound microenvironment, a family of functionalised (atelo)collagen 
networks has recently been developed, whereby inherent control of MMP activity is 
accomplished via the introduction of chemically-coupled photoactive compounds [75,76].  
 
Figure 13.5. (A): Synthesis of UV-cured (atelo)collagen networks via lysine functionalisation with 
photoactive compounds. (B): Resulting (atelo)collagen networks swell in water and present an internal 
porous architecture (C) by SEM. (D): Atomic force microscopy on collagen hydrogels reveal significantly 
different elastic modulus (EAFM) depending on the specific network architecture. 
 
 
The covalent functionalisation of (atelo)collagen triple helices with photoactive compounds 
enables (i) the formation of photo-induced covalent networks with bespoke macroscopic 
properties and (ii) the complexation of introduced adducts with the active site of MMPs, yet 
avoiding the use of any soluble factor. This synthetic strategy proved to enable customisation 
of hydrogel elastic modulus depending on the type of chemically-coupled photoactive adduct 
(Figure 13.5), whilst an averaged swelling ratio of up to nearly 2000 wt.-% was observed [77]. 
Preclinical investigations with a Hydrogel of Functionalised ateloCollagen (HyFaCol) indicated 
GMA* 4VBC* MA*
(A)
(B) (C) (D)
increased neodermal response in full thickness wounds created in diabetic mice, compared to 
wounds treated with a polyurethane commercial control in the same experimental conditions 
[78]. 
 
13.4.2 Customisation into single fibrous component for wound dressing manufacture 
The clinical performance of multifunctional collagen-based formulations would be greatly 
accelerated if delivered in material formats relevant to the wound dressing manufacturing 
industry. Fibrous architectures, e.g. nonwovens, are widely used for the development of 
healthcare materials, including wound dressings, due to their high porosity, easy manufacture 
and advantageous fluid adsorption properties [79]. Consequently, the creation of single 
collagen fibres has been widely pursued aiming to accomplish libraries of dressing building 
blocks with customised molecular architecture, properties and biofunctionalities, to fulfil the 
complex requirements of stratified chronic wounds. To deliver on this vision, specific 
manufacturing routes need to be developed enabling preservation of collagen proteinic 
architecture in the fibrous state, whilst allowing for clinically-acceptable material purity and 
manufacturing yield relevant for industrial scale up. 
Among the different fibre manufacturing processes available, wet spinning has the potential 
to convert collagen solutions into single fibres. From a protein preservation standpoint, this 
fibre spinning process is highly benign since there is no involvement of either harsh organic 
solvents, electrostatic voltage or high temperature [80]. In these experimental conditions, the 
risk of spinning-induced collagen triple helix denaturation is minimised, so that wet spun fibres 
consisting of preserved collagen triple helices can be obtained. Wet spinning was developed 
by the textile industry in the early 1900s as a means of producing man-made fibres such as 
viscose rayon. Mechanistically, this fibre spinning mechanism relies on (i) the phase 
separation of a fibre-forming (bio)polymer solution against a suitable (bio)polymer non-solvent 
and on (ii) the spinning rate of the phase-separating solution jet. The (bio)polymer solution is 
extruded through a spinneret into a non-solvent coagulation bath, whereby (bio)polymer 
solution streams turn into solid filaments, due to the non-solvent-induced (bio)polymer phase 
separation. For each (bio)polymer system, fibre properties can therefore be manipulated by 
adjusting solution and coagulating bath characteristics, wet-spinning parameters (e.g. 
spinneret diameter, solution injection flow rate, drawing ratio) and post-spinning fibre 
conditioning (e.g. covalent crosslinking, washing, drying). 
Silver et al. pioneered the formation of high strength, dehydrothermally-crosslinked, wet 
spun collagen fibres using concentrated rat tail collagen solutions in diluted hydrochloric acid 
[81,82]. Wet spinning was carried out in a neutral buffer system at 37 ºC, whereby resulting 
fibres were washed in isopropyl alcohol and distilled water prior to dehydrothermal 
crosslinking. Remarkably, hydrated wet spun fibres exhibited a maximum tensile strength and 
elongation at break of up to 92 MPa and 20%, respectively, although the density of the 
covalent crosslinks could not be quantified. Using a PEG-containing coagulating bath, 
Zeugolis et al. successfully wet spun bovine atelocollagen fibre with in vitro reconstituted 
fibrillary organisation and increased tensile strength [83]. Post-spinning incubation in 
isopropanol induced a decrease in fibre diameter compared to fibres conditioned in aqueous 
environment, likely related to fibre dehydration in the former case and water-induced fibre 
swelling in the latter case. Hydrated wet spun fibres displayed an elastic modulus of more than 
16 MPa when incubated in PBS, and of nearly 4 MPa when incubated in distilled water, 
suggesting that PBS incubation induced folding of collagen triple helices into fibrils. In another 
account, wet spun collagen was incubated with crosslinking agents, resulting in fibres 
resembling the tensile properties of native tissues. Either ethylene glycol diglycidyl ether and 
hexamethylene diisocyanate (HDI) proved suitable in enhancing the mechanical properties of 
wet spun collagen, although concerns were also raised regarding potential material 
cytotoxicity and side reactions [47]. To minimise the extent of superficial irregularities, e.g. 
ridges and crevices, following fibre air drying and increase molecular alignment and fibre 
tensile properties, Caves et al. applied drawing to wet spun fibres. A dual syringe pump system 
was developed where isolated collagen solution and PEG-based wet spinning buffer were 
mixed in 1-m fluoropolymer tubing before entering in a 2-m ringing bath of 70% ethanol 
solution [84]. Resulting filaments displayed retained triple helix organisation, whilst 
reconstituted collagen fibrils were also observed following 48-hour incubation in PBS at 37 ºC 
and washing in distilled water, prior to fibre crosslinking with glutaraldehyde. Hydrated fibres 
displayed a fibre diameter in the range of 20-50 µm and an averaged ultimate tensile strength 
of nearly 94 MPa. Treatment with glutaraldehyde proved successful in decreasing the extent 
of fibre degradation following subcutaneous implantation in C57BL/6 mice, although a mild 
local inflammatory response was observed. Integrated wet spinning-crosslinking processes 
have also been attempted, whereby fibre-forming collagen was wet spun (with no drawing) in 
a mineral salt aqueous coagulation bath containing glutaraldehyde [85]. Despite grooved 
surface morphology was observed, resulting fibres could be successfully assembled in a 
carded nonwoven architecture. This study therefore supported the use of wet spinning for the 
formation of fibrous assemblies based on triple helix preserved collagen, in contrast to the use 
of e.g. melt spinning, whereby fibres of completely denatured collagen are obtained [86]. Other 
than animal-derived collagen, recombinant human type I collagen derived from a transgenic 
tobacco plant was recently applied in a novel fibre spinning method, involving drawing and 
crosslinking [23]. Smooth, highly aligned wet spun fibres with a fibre diameter as small as 8 
µm could be successfully accomplished. Also in this case, potentially toxic glutaraldehyde and 
carbodiimide-induced crosslinking was pursued, whereby the former treatment led to fibres 
with increased wet-state stress at break (~140 MPa) compared to carbodiimide-crosslinked 
fibres (~40 MPa). To address the cytotoxicity issues associated with glutaraldehyde or 
carbodiimide, a photoactive collagen system has been recently developed and employed as 
fibre building block [87]. Photoactive collagen proved to be compatible with the wet spinning 
process in either alcohol or water-based coagulating baths. Water-insoluble, mechanically-
competent fibres could be prepared via post-spinning UV-curing process, and successfully 
assembled into a three-dimensional porous fabric (Figure 13.6). Other than wet spinning, 
microfluidics-based approaches have also been proposed for the fabrication of reconstituted 
type I collagen fibres with fibre diameters of only 3 µm and an averaged tensile strength of 
383 MPa [88].  
 
Figure 13.6. Manufacture of a collagen fabric with retained triple helices. 4VBC-functionalised collagen 
(1) is dissolved in acidic solution and wet spun. UV-cured staples (2) are water insoluble and 
mechanically competent, and can be assembled into a three-dimensional fabric via e.g. dry laying (3). 
 
 
Despite the remarkable performance of resulting fibres and the absence of crosslinking step, 
further research may be required into this process to increase its 19 m·h−1 production rate 
towards wet spinning-like fibre production rates of 1000 m·h-1 [23] to enable industrial scale 
up.   
 
13.4.3 Direct manufacture of multifunctional collagen-based meshes 
Together with the multiscale manufacture of fabric dressings via controlled customisation 
of multifunctional molecular systems into single fibres and consequent fibre assembly into 
three dimensional structures, one-step spinning processes have also been extensively 
investigated for the creation of fibrous meshes from collagen-based solutions. Such research 
approaches undoubtedly offer a faster manufacturing route to the fibrous prototype, although 
(1) Photoactive collagen
(2) Collagen staples
Dry laying
(3) Collagen fabric
reduced controlled over fibre characteristics, protein organisation and production yield is 
expected [36,80,86]. Electrospinning and wet electrospinning of collagen-based materials 
have been extensively employed for the formation of either mono- or multi-layered nonwoven 
fabrics, whilst other strategies involving physical or chemical deposition of collagen coatings 
onto fibrous supports have also been pursued. 
Electrospinning is considered as a simple and effective fabrication method to prepare 
nanofibrous membranes with diameters ranging from 5 to 500 nm, i.e. about 100 times smaller 
than the fibre diameters observed in wet or melt spun fibres. Electrospinning involves the 
application of voltage to a syringe containing a polymer solution [89]. Following ejection of the 
polymer solution and solvent evaporation, a nonwoven mesh is formed on a grounded 
collector. Despite fibre and web characteristics can be manipulated by adopting appropriate 
experimental parameters, such as solvent, polymer concentration, and flow rate, common 
process limitations include the limited fabric thickness and restricted fabric porosity. 
Furthermore, given that electrospinning requires volatile solvent to allow for prompt fibre 
formation, organic solvents are usually. In the case of collagen, both applications of 
electrostatic voltage and organic solvents are well known to induce unwinding of collagen triple 
helices into randomly-coiled polypeptide chains, so that resulting mesh is effectively 
composed of gelatin rather than collagen [90,91]. Due to the loss of collagen triple helices, 
resulting samples are readily soluble in aqueous environment, preventing their use in 
biological environments. Consequently, the formation of water-stable collagen-based 
electrospun membranes has attracted widespread research attention and has so far been 
typically accomplished via blending of collagen solution with other polymers [35], manufacture 
of multi-layered structures [92,93,94], chemical crosslinking of resulting fibres [95,96,97], or 
combination thereof. These approaches proved successful towards the creation of ECM-
mimetic fabrics integrated with growth factor retention and release functionality [98]. Here, a 
polysaccharide component allowed for the effective sequestration of endogenous platelet-
derived growth factor; whilst, the enzymatic cleavage of gelatin in the electrospun matrix 
triggered the release of sequestered growth factor, so that accelerated repair of a full-
thickness skin wound was observed in C57BL/6 mice. 
To overcome the cytotoxicity issues with conventional crosslinking methods, e.g. 
glutaraldehyde, Dhand et al. have recently proposed the addition of naturally occurring 
catecholamines in collagen-based electrospinning solutions, so that fibre stabilisation is 
accomplished via latent oxidative polymerization initiated by exposure to ammonium 
carbonate [99]. In another recent report, wet electrospinning has been proposed to address 
the limited thickness, porosity and pore size observed in electrospun fabrics [100]. Wet 
electrospinning proceeds by spraying electrospun nanofibers into a liquid bath, which is used 
to separate the fibers. By controlling the area of nanofiber deposition, resulting wet electrospun 
webs revealed a porosity of about 90 vol.%, in contrast to 60-80 vol.% porosity observed in 
electrospun samples. Other approaches have also been investigated to avoid inherent 
electrospinning-associated denaturation of triple helices. Collagen has been deposited as 
physical coating onto polyester/gelatin electrospun meshes, yet rapid collagen degradation 
was observed during 24-hour enzymatic incubation. Chemical immobilisation of collagen 
coating has therefore been proposed by using polypropylene (PP) meshes as inert substrate 
for biomimetic functionalisation [101]. Plasma modification of PP was applied to enable the 
incorporation of acrylic moieties, which could then be activated with carbodiimide to covalently 
couple collagen. Although the enzymatic stability of the coating was not addressed, application 
of resulting material on to a full thickness wound model in SD rats revealed increased wound 
closure with respect to wounds treated with PP controls. Similar approach was also pursued 
in an N-isopropyl acrylamide (NIPAM)-grafted PP nonwoven fabric, whereby covalent 
glutaraldehyde-mediated covalent linkages were proposed between collagen and NIPAM was 
proposed [102].  
 
 
 
 
13.5 Outlook 
Different advanced wound care concepts will continue to be developed to support chronic 
wound healing, which will rely on new antibiofilm technologies, multifunctional material design, 
as well as flexible and scalable manufacture. A strong focus will be on integrated collagen-
based dressings that will allow remote monitoring of wound conditions and visual indications 
of chronic state changes. This approach will enable timely and prolonged application of cost-
effective dressing devices promptly customised to the targeted chronic wound, ultimately 
resulting in economically-affordable wound healing times, and minimised dressing changes 
and risks of infection. Flexible design and manufacturing concepts should therefore be 
developed, which can enable systematic variations in dressing properties and functions, whilst 
also allowing for late stage device assembly at the bed side. Especially in out-of-hospital 
healthcare, collagen devices that are able to adjust to and regulate changes in chronic wound 
microenvironment, whilst also displaying easy removability, are expected to reduce patient 
pain, therapeutic time and wound infection risks. These requirements could be fulfilled by 
systems that are able to perform and display more than one function according to defined 
biochemical shifts. Advances in collagen-compatible fibre spinning and assembling 
technologies will be paramount to realise high-value building blocks with integrated sensing 
units and to enable the conversion into appropriate structures depending on the chronic wound 
type, state and size. Patient- and clinician-assisted device development will continue to be key 
to de-risk late-stage clinical failure and to identify appropriate clinical models for first-in-man 
evaluations, prior to clinical trials.   
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